Positive findings from the APPROACH study, which reached its primary end point, and showed the efficacy of volanesorsen therapy for patients with famimlial chylomicronemia syndrome (FCS).
All articles by Lea Eslava-Kim, PharmD
A positive phase 3 study showed that patients treated with LJPC-501 were likely to achieve pre-specified blood pressure targets vs placebo.
Publish Date
A new drug application for warafin potassium has been submitted to the FDA.
Publish Date
-
Latest News Your top articles for Saturday
For More Personalized News -
Haymarket Medical NetworkTop Picks
- Loading...
Continuing Medical Education (CME/CE) Courses